Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Lauwe – page 80

2 294 clinical trials in Lauwe, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Lauwe at a glance
2 294
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 294 trials in Lauwe

Open in trial search

Colitis ulcerative+1

Not yet recruiting

Study of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Endometrial cancer

Not yet recruiting

Maintenance Treatment Study of gsk5733584 with dostarlimab or pembrolizumab in patients with mismatch repair proficient advanced or recurrent endometrial cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

COVID-19+1

Not yet recruiting

Safety and immune response of investigational mRNA vaccine GSKVX000000078664 versus drug combination in adults with flu and COVID-19

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Elasomeran
  • Sponsor:GlaxoSmithKline Biologicals

Safety and Efficacy of GSK5764227 with Abiraterone Acetate and Enzalutamide in Metastatic Castration‑Resistant Prostate Cancer Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Glaxosmithkline Research & Development Limited

Urinary tract infection

Not yet recruiting

A study of fosfomycin trometamol treatment for male urinary tract infections in primary care settings

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fosfomycin Trometamol
  • Sponsor:Centre Hospitalier Universitaire Rouen

Transitional cell carcinoma

Not yet recruiting

Neoadjuvant Study of Avelumab with Gemcitabine and Cisplatin versus Chemotherapy Alone in Patients with High‑Grade Localized Upper Tract Urothelial Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Centre Hospitalier Universitaire De Nimes

Immune response and safety of revaccination with respiratory syncytial virus glycoprotein F recombinant vaccine adjuvanted with AS01E in older adults

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years · Healthy volunteers
  • Substances:GSKVx000000017064
  • Sponsor:GlaxoSmithKline Biologicals

Malignant peritoneal neoplasm+2

Not yet recruiting

A Phase 3 Study of Raludotatug Deruxtecan With or Without Bevacizumab as Maintenance Therapy in Patients With Platinum‑Sensitive Recurrent Ovarian Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Daiichi Sankyo Inc.

Ravulizumab versus plasma exchange for acute neuromyelitis optica attacks: a randomized trial in patients with first or relapsed episodes

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Antiphospholipid syndrome

Not yet recruiting

Stopping warfarin sodium, fluindione, or acenocoumarol in low‑risk thrombotic antiphospholipid syndrome patients after antibody loss

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acenocoumarol
  • Sponsor:Assistance Publique Hopitaux De Paris

Partial seizures

Not yet recruiting

Phase 3 Randomized Study of RAP-219 to Reduce Seizure Frequency in Adults with Focal Epilepsy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Rapport Therapeutics Inc.

Pruritus

Not yet recruiting

Efficacy and safety of remibrutinib, pimecrolimus and tacrolimus in adults with severe chronic pruritus of unknown origin (CPUO): a randomized, placebo‑controlled trial

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pimecrolimus
  • Sponsor:Novartis Pharma AG

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Lauwe

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical research focusing on proton pump inhibitor (PPI) de-prescribing strategies in primary care settings. The trials examine alternative approaches for patients with functional dyspepsia and reflux conditions.

  • PPI Usage Optimization
  • Digestive Health Management
  • Alternative Treatment Strategies

These studies aim to establish more effective methods for transitioning patients from long-term PPI therapy to alternative management approaches.

02 Primary Care Innovation

Groundbreaking research comparing different therapeutic approaches for managing chronic acid-related conditions. The study evaluates on-demand medication use versus alternative treatments.

  • Patient-Centered Care
  • Medication Management
  • Treatment Optimization

This research focuses on developing evidence-based strategies for reducing long-term medication dependency while maintaining symptom control.

03 Digestive Health Studies

Clinical investigations exploring the effectiveness of alginate-based therapies compared to traditional acid-suppression treatments for various digestive conditions.

  • Therapeutic Alternatives
  • Symptom Management
  • Clinical Outcomes

The research aims to identify optimal treatment pathways for patients with chronic digestive symptoms requiring long-term care.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.